Related Experiment Videos
Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells
K Nishio1, K Fukuoka, H Fukumoto
1Pharmacology Division, National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.
Abstract:
Mitogen-activated protein kinase (MAPK) pathway is proposed to be a therapeutic target for cancer cells. In order to find the potential therapeutic usefulness of MAPK for cancer cells, the effect of EAS1, an antisense oligonucleotide for an MAPK, on cancer-cell-growth were investigated in vitro. EAS1 effectively inhibited the growth of several human lung cancer cell lines such as PC-14 cells upon exposure to 10-0-10-1 microM of EAS1 determined dye-formation (MTT) assay. The ED50 values were comparable to those obtained for the inhibition of MAPK activity, DNA synthesis. EAS1 arrested the PC-14 cells at the G2/M phase of cell cycle followed by apoptosis in a dose-dependent manner. In order to determine the factors which influence the cellular sensitivity against MAPK inhibition, the effect of EAS1 on H-ras-transformed murine fibroblast cells were compared with that on parental cells. The NIH3T3 cells transformed by the H-ras gene (PT22-3) showed higher sensitivity against the effects of EAS1. Because MAPK activity was activated by H-ras gene transfection in PT22-3, the status of the MAPK cascade in cells was the determining factor for the efficacy of EAS1. In addition, cell permeabilization by digitonin enhanced the growth inhibitory effect of EAS1. Penetration of the cell membrane by EAS1 is also crucial for the growth inhibitory effect of EAS1. In conclusion, MAPK is an important target for cancer treatment and MAPK antisense oligonucleotide is a potentially significant antitumor oligonucleotide.
Insights
Mitogen-activated protein kinase (MAPK) pathway inhibition using EAS1, an antisense oligonucleotide, effectively suppressed lung cancer cell growth in vitro. Cellular sensitivity to EAS1 depends on the MAPK cascade status and cell membrane penetration.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The mitogen-activated protein kinase (MAPK) pathway is a critical regulator of cell proliferation and survival.
- Aberrant MAPK signaling is implicated in the development and progression of various cancers.
- Targeting the MAPK pathway presents a promising therapeutic strategy for cancer treatment.
Purpose of the Study:
- To investigate the therapeutic potential of EAS1, an antisense oligonucleotide targeting MAPK.
- To evaluate the in vitro efficacy of EAS1 against human lung cancer cell lines.
- To identify factors influencing cellular sensitivity to MAPK inhibition.
Main Methods:
- In vitro cell culture of human lung cancer cell lines (e.g., PC-14) and murine fibroblast cells (NIH3T3 and H-ras-transformed PT22-3).
- Dye-formation (MTT) assay to determine cell viability and growth inhibition.
- Cell cycle analysis to assess G2/M phase arrest and apoptosis.
- Assessment of MAPK activity and DNA synthesis inhibition.
- Evaluation of cell permeabilization effects using digitonin.
Main Results:
- EAS1 demonstrated significant inhibition of lung cancer cell growth in a dose-dependent manner.
- The efficacy of EAS1 correlated with MAPK activity and was enhanced in H-ras-transformed cells.
- EAS1 induced G2/M cell cycle arrest and apoptosis.
- Cell permeabilization enhanced the growth inhibitory effects of EAS1, indicating the importance of cellular uptake.
Conclusions:
- The MAPK pathway is a crucial target for cancer therapy.
- MAPK antisense oligonucleotides, such as EAS1, hold significant potential as antitumor agents.
- Cellular factors, including MAPK cascade status and membrane permeability, are critical determinants of EAS1 efficacy.